DelveInsight has launched a new report on “Tenosynovial Giant Cell Tumors – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Tenosynovial Giant Cell Tumors – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Tenosynovial Giant Cell Tumors Market Report:

• As per Delveinsight estimates, the total diagnosed incident population of Tenosynovial Giant Cell Tumors (TSGCTs) in the seven major markets was found to be 13,580 cases in 2017.
• As per Delveinsight estimates in the EU5 countries, Germany had the maximum diagnosed incident population of TSGCTs i.e., 953 cases followed by the United Kingdom with 726 cases in 2017. While the lowest number of cases were found in Spain with 551 cases in 2017.
• Japan accounted for 2,346 cases of diagnosed Tenosynovial Giant Cell Tumors (TSGCTs) in 2017, which is expected to increase in the forecast period 2021–2030.

Key benefits of the report:

1. Tenosynovial Giant Cell Tumors market report covers a descriptive overview and comprehensive insight of the Tenosynovial Giant Cell Tumors Epidemiology and Tenosynovial Giant Cell Tumors  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Tenosynovial Giant Cell Tumors market report provides insights on the current and emerging therapies.
3. Tenosynovial Giant Cell Tumors market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Tenosynovial Giant Cell Tumors market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Tenosynovial Giant Cell Tumors market.

Tenosynovial Giant Cell Tumors Overview

Tenosynovial giant cell tumors (TSGCT) are a group of neoplastic disorders that involve synovium-lined tendon sheaths, synovial joints, and adjacent soft tissue. These are locally aggressive, soft tissue lesions characterized by inflammation of the synovial lining among joints and tendons. These neoplasms are thought to arise via overexpression of the colony-stimulating factor 1 receptor. TSGCTs are alsoknown as giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumor of the tendon sheath (PVNTS), extra-articular pigmented villonodular tumor of the tendon sheath, or localized or focal nodular synovitis. 

Tenosynovial Giant Cell Tumors Market 

The dynamics of the Tenosynovial Giant Cell Tumors market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Five Prime Therapeutics, Novartis, Deciphera Pharmaceuticals, AmMax Bio, Daiichi Sankyo, and others during the forecasted period 2018-2030.

Learn more by requesting for sample@ Tenosynovial Giant Cell Tumors Market Landscape 

Tenosynovial Giant Cell Tumors Pipeline Therapies and Key Companies 

• Cabiralizumab: Five Prime Therapeutics
• Nilotinib: Novartis
• DCC-3014: Deciphera Pharmaceuticals
• Lacnotuzumab: Novartis
• AMB-05X: AmMax Bio 
• Turalio: Daiichi Sankyo

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Tenosynovial Giant Cell Tumors Patient Share (%) Overview at a Glance

5. Tenosynovial Giant Cell Tumors Market Overview at a Glance

6. Tenosynovial Giant Cell Tumors Disease Background and Overview

7. Tenosynovial Giant Cell Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Tenosynovial Giant Cell Tumors 

9. Tenosynovial Giant Cell Tumors Current Treatment and Medical Practices

10. Unmet Needs

11. Tenosynovial Giant Cell Tumors Emerging Therapies

12. Tenosynovial Giant Cell Tumors Market Outlook

13. Country-Wise Tenosynovial Giant Cell Tumors Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Tenosynovial Giant Cell Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Tenosynovial Giant Cell Tumors Pipeline 

“Tenosynovial Giant Cell Tumors Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Tenosynovial Giant Cell Tumors market. A detailed picture of the Tenosynovial Giant Cell Tumors pipeline landscape is provided, which includes the disease overview and Tenosynovial Giant Cell Tumors treatment guidelines.

Tenosynovial Giant Cell Tumors Epidemiology

DelveInsight’s ‘Tenosynovial Giant Cell Tumors  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Tenosynovial Giant Cell Tumors epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/